Chaochen N. Wang

Kobe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Genetically Engineered Light-Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple-Negative Breast Cancer.

Genetically Engineered Light-Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple-Negative Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 11, 2025

Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study.

Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study.

Journal: Modern rheumatology

Published: June 26, 2025

Floquet topological state induced by light-driven band inversion in SnTe.

Floquet topological state induced by light-driven band inversion in SnTe.

Journal: Nature physics

Published: January 21, 2025

Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan.

Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan.

Journal: International journal of clinical oncology

Published: July 16, 2024

Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.

Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.

Journal: Targeted oncology

Published: April 05, 2024

Clinicopathological and molecular characteristics of esophageal carcinoma with ductal differentiation: analysis of 17 cases

Clinicopathological and molecular characteristics of esophageal carcinoma with ductal differentiation: analysis of 17 cases

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: March 03, 2024

Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan.

Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan.

Journal: International journal of dermatology

Published: February 13, 2024

Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma

Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: January 22, 2024

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: December 26, 2023

Bowel Urgency in Patients with Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Real-World Survey in Japan.

Bowel Urgency in Patients with Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Real-World Survey in Japan.

Journal: Advances in therapy

Published: July 07, 2023

Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.

Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.

Journal: The Journal of dermatological treatment

Published: July 05, 2023

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Journal: Breast cancer research : BCR

Published: January 10, 2023

Showing 1-12 of 55

Last Updated: 09/26/2026